Quantcast

Latest Monoclonal antibodies Stories

2014-04-10 08:28:53

NEW YORK, April 10, 2014 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic...

2014-04-08 08:32:31

Additional preclinical data highlights the pharmacologic properties of PEGPH20 SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the American Association for Cancer Research (AACR) annual meeting being held in San Diego. The first presentation includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of...

2014-04-07 04:21:25

BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ -- New findings to be presented at the American Association for Cancer Research annual meeting arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody(TM) platform has identified four 'hotspots' on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET...

2014-04-04 16:23:39

TARRYTOWN, N.Y., April 4, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has elected Robert A. Ingram to its Board of Directors. Regeneron also announced that Dr. Eric Shooter, a co-founder of the Company, is retiring from the Board after nearly 26 years of service to Regeneron. Mr. Ingram was nominated to become a member of Regeneron's Board by Sanofi. Under the terms of an investor agreement between Regeneron and Sanofi, Sanofi...

2014-04-03 20:22:32

SOUTH SAN FRANCISCO, Calif., April 3, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conference: -- 13(th) Annual Needham Healthcare Conference Tuesday, April 8, 2014 at the Westin Grand Central Hotel in New York City, NY 11:20AM - 11:50AM US ET (8:20AM - 8:50AM US PT) Presentations will include overviews of the company's KB001-A development program to...

2014-04-03 08:29:04

-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE, April 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement?mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2),...

2014-04-03 04:20:52

CAMBRIDGE, England, April 3, 2014 /PRNewswire/ -- GBP19.5M raised to drive development of best-in-class fully human VH antibody fragment therapeutics Crescendo Biologics Limited (Crescendo) today announces it has raised a further GBP2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals GBP19.5m. It was led by Imperial Innovations and included new...

2014-04-01 00:21:53

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer. The registration trial referred to as TRIBECA(TM) (TRIal designed to evaluate BioEquivalence...

2014-03-31 16:26:29

EMERYVILLE, Calif. and OSAKA, Japan, March 31, 2014 /PRNewswire/ -- Trianni, Inc. ("Trianni") and Takeda Pharmaceutical Company Limited ("Takeda") jointly announced today that they have entered into a license agreement for Takeda's use of the Trianni Mouse, a monoclonal antibody discovery platform. Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the...

West Nile Virus May One Day Help Fight West Nile Virus
2014-03-30 05:57:16

Brett Smith for redOrbit.com - Your Universe Online Tobacco is commonly associated with causing disease, but a new methodology developed by scientists at Arizona State University and several other institutions uses the plant to generate a potential therapy for treating West Nile virus – which currently has no cure. According to a report published on Thursday in the open-access journal PLOS ONE, the team used tobacco to generate monoclonal antibodies (MAbs) and their derivatives, which...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related